BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

While radiation therapy has been in use for more than 100 years, innovations including linear accelerators, imaging, and AI ...

Floating in the Rio Negro river in the Brazilian Amazon, Luiz Felipe, who has Down Syndrome, beams as he hugs a pink dolphin ...

In collaboration with Hitachi, the National Cancer Centre Singapore has introduced Proton Beam Therapy - a treatment designed to target tumours with precision while reducing the impact on healthy ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

The presentation will be available on IBA's investor relations website and on ...

One of the youngest victims of proposed NIH funding cuts would be six-year-old Cailen Vela of Michigan, who has a rare and ...

Tatum O'Neal, the youngest Oscar winner in history, tells all to Variety about surviving drug addiction, a stroke and life ...